| Date Filed | Type | Description |
| 10/03/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 08/22/2023 |
4
| Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC|
Txns:
| Paid exercise price by delivering 317 shares
@ $7.14, valued at
$2.3k
Exercised 655 restricted stock units
@ $0 |
|
| 08/18/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/18/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 08/08/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/08/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/08/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Unregistered Sales of Equity Secu...|
Docs:
|
"SECURITIES SUBSCRIPTION AGREEMENT This SECURITIES SUBSCRIPTION AGREEMENT is made and entered into this 8th day of August, 2023 by and among Novavax, Inc., a Delaware corporation having a place of business at 21 Firstfield Rd., Gaithersburg, MD 20878 , and SK bioscience Co., Ltd., a company incorporated in the Republic of Korea having a place of business at 310 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13494, Republic of Korea . The Company and SK shall each be hereinafter referred to as a “Party” and collectively as the “Parties”. WHEREAS, the Company and SK are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded by Section 4 of the Securities Act of 1933, as amended ; and WHEREAS, the Company desires to issue to SK, shares of ..." |
|
| 08/08/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/11/2023 |
8-K
| Quarterly results |
| 07/07/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement Interactive Data |
| 06/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 12.1% stake in AMENDED FILING NOVAVAX INC |
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 04/28/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 04/28/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/27/2023 |
SC 13D
| Form SC 13D - General statement of acquisition of beneficial ownership: |
| 04/18/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 04/04/2023 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
| 03/22/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 03/14/2023 |
4
| Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC|
Txns:
| Exercised 4,609 shares
@ $6.52, valued at
$30.1k
Paid exercise price by delivering 2,471 shares
@ $6.52, valued at
$16.1k
Exercised 4,609 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Kelly James Patrick (EVP, CFO and Treasurer) has filed a Form 4 on NOVAVAX INC|
Txns:
| Exercised 4,609 shares
@ $6.52, valued at
$30.1k
Paid exercise price by delivering 2,471 shares
@ $6.52, valued at
$16.1k
Exercised 4,609 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Herrmann John A III (EVP, Chief Legal Officer) has filed a Form 4 on NOVAVAX INC|
Txns:
| Exercised 4,609 shares
@ $6.52, valued at
$30.1k
Paid exercise price by delivering 1,780 shares
@ $6.52, valued at
$11.6k
Exercised 4,609 restricted stock units
@ $0 |
|
| 03/14/2023 |
4
| Glenn Gregory M (President, R&D) has filed a Form 4 on NOVAVAX INC|
Txns:
| Bought 3,000 shares
@ $7.4845, valued at
$22.5k
Bought 2,000 shares
@ $7.044, valued at
$14.1k
Bought 1,000 shares
@ $6.5, valued at
$6.5k
Exercised 6,298 shares
@ $6.52, valued at
$41.1k
Paid exercise price by delivering 2,432 shares
@ $6.52, valued at
$15.9k
Exercised 6,298 restricted stock units
@ $0 |
|
| 03/14/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
4
| Trizzino John (EVP, CCO and CBO) has filed a Form 4 on NOVAVAX INC|
Txns:
| Granted 100,100 options to buy
@ $6.97, valued at
$697.7k
Granted 86,670 restricted stock units
@ $0 |
|
| 03/09/2023 |
4
| Kelly James Patrick (EVP, CFO and Treasurer) has filed a Form 4 on NOVAVAX INC|
Txns:
| Granted 42,350 options to buy
@ $6.97, valued at
$295.2k
Granted 36,670 restricted stock units
@ $0 |
|
| 03/09/2023 |
4
| Herrmann John A III (EVP, Chief Legal Officer) has filed a Form 4 on NOVAVAX INC|
Txns:
| Granted 44,280 options to buy
@ $6.97, valued at
$308.6k
Granted 38,330 restricted stock units
@ $0 |
|
| 03/02/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/28/2023 |
S-3ASR
| Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers: |
|